HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a maintained price target of $33.
March 12, 2024 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals has been reiterated with a Buy rating and a price target of $33 by HC Wainwright & Co. analyst Andrew Fein.
The reiteration of a Buy rating and maintenance of a $33 price target by a reputable analyst suggests a positive outlook for ACADIA Pharmaceuticals. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100